<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

CAR-T poised to create ‘paradigm shift’ in non-Hodgkin lymphoma

minute read

by Healio | February 14, 2022
placeholder

It has been about 2 decades since such effective new therapeutics have been developed for this high-risk population, according to Manali Kamdar, associate professor of medicine/hematology at University of Colorado School of Medicine and clinical director of lymphoma services at CU Cancer Center.

Topics: Press Coverage